Abstract
Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 229-233 |
| Number of pages | 5 |
| Journal | Circulation Research |
| Volume | 117 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 17 2015 |
| Externally published | Yes |
Keywords
- cell- and tissue-based therapy
- chronic heart failure
- clinical trial
- heart disease
- mesenchymal stem cells
ASJC Scopus subject areas
- Physiology
- Cardiology and Cardiovascular Medicine